8-K
filed August 16, 2022, 7:59 PM ET
ticker PMCB
CIK 0001157075
other material
confidence high
sentiment positive
materiality 0.75
PharmaCyte (PMCB) reaches cooperation deal with Iroquois; appoints five new independent directors
PharmaCyte Biotech, Inc.
- Five prior directors resigned; five new directors appointed to reconstituted 7-member board effective Aug 15, 2022.
- Iroquois, holding ~6.7% stake, gets two appointees (Schechter, Silverman); standstill until Sept 30, 2024 or later.
- New independent directors: Allen, Farb, Stover join existing directors Waggoner and Abecassis.
- New directors receive $12,500/quarter cash retainer, 334 shares, and option for 334 shares with five-year term.
- Iroquois agreed to customary standstill, including voting and ownership limits (14.9% cap) through standstill period.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Farb was appointed as director at PharmaCyte Biotech, Inc..
- Action
- appointed
- Role
- director
Exact text from the filing
effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Matthias Löhr resigned as director at PharmaCyte Biotech, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Allen was appointed as director at PharmaCyte Biotech, Inc..
- Action
- appointed
- Role
- director
Exact text from the filing
effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Stover was appointed as director at PharmaCyte Biotech, Inc..
- Action
- appointed
- Role
- director
Exact text from the filing
effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Tong resigned as director at PharmaCyte Biotech, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mr. Liquard resigned as director at PharmaCyte Biotech, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Schechter was appointed as director at PharmaCyte Biotech, Inc..
- Action
- appointed
- Role
- director
Exact text from the filing
effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Silverman was appointed as director at PharmaCyte Biotech, Inc..
- Action
- appointed
- Role
- director
Exact text from the filing
effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Crabtree resigned as director at PharmaCyte Biotech, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mr. Trujillo resigned as director at PharmaCyte Biotech, Inc..
- Action
- resigned
- Role
- director
Exact text from the filing
effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.